A case of primary Sjögren syndrome masquerading as post-COVID Bickerstaff encephalitis

Shawn Zhi Zheng Lin, Hua Chan Ling, You‐Jiang TanNeurology 2024 · DOI

Abstract

We present a case of acute external ophthalmoplegia, hypersomnolence, and ataxia occurring 5 days after an episode of SARS-CoV-2 upper respiratory tract infection. The patient’s serum returned positive for anti-GD1a antibodies. Guided by precedent cases, she was empirically started on a course of intravenous (IV) immunoglobulin for possible para-infectious Bickerstaff brainstem encephalitis (BBE). However, she failed to respond and subsequently developed autoimmune hemolytic anemia as well as renal tubular acidosis (type 1). Corroborative history from her family elucidated constitutional and sicca symptoms and she was eventually diagnosed with primary Sjögren syndrome (pSS) complicated by brainstem and cerebellar involvement. She was treated with IV cyclophosphamide and rituximab, after which her neurological deficits completely resolved at two months.

Introduction

The medical community continues to explore the diverse immunological interactions of SARS-CoV-2. A recognized complication is the development of "para-infectious" syndromes, where the host immune response to the virus targets the nervous system. Bickerstaff brainstem encephalitis (BBE) is a rare manifestation characterized by ophthalmoplegia, ataxia, and impaired consciousness.

However, diagnostic challenges arise when systemic autoimmune diseases mimic these post-viral syndromes. Primary Sjögren Syndrome (pSS), while typically associated with sicca symptoms (dry eyes and mouth), involves the central nervous system (CNS) in 2-25% of cases. This case highlights the risk of diagnostic anchoring, where a post-COVID-19 presentation and positive anti-GD1a antibodies initially suggested BBE, masking an underlying systemic autoimmune process triggered or unmasked by the viral infection.

Methods

This clinical case report documents the diagnostic and therapeutic trajectory of a 69-year-old female.

  • Initial Diagnostics: Brain MRI (T2-weighted), cerebrospinal fluid (CSF) analysis, and nerve conduction studies were performed.
  • Serological Testing: A comprehensive panel was conducted, including anti-GD1a antibodies and paraneoplastic markers.
  • Diagnostic Re-evaluation: Following a lack of response to IV immunoglobulin (IVIG), the investigation was expanded to include Schirmer’s test, CT imaging of the salivary glands, and testing for anti-Ro and anti-La antibodies.
  • Therapeutic Intervention: Treatment transitioned from standard IVIG to aggressive immunosuppression with intravenous cyclophosphamide and rituximab.

Key Insights and Ideas

A critical finding was the presence of anti-GD1a antibodies, which often serve as a marker for BBE or Miller Fisher syndrome. In this context, the authors suggest SARS-CoV-2 may have induced a polyclonal humoral response, producing "noisy" antibodies that were incidental rather than primary drivers of the pathology.

The case posits that SARS-CoV-2 may trigger pSS through molecular mimicry or bystander activation, where viral-induced cytokine storms lead to B-cell hyperactivation. Furthermore, the diagnosis relied heavily on identifying "sicca" symptoms and constitutional weight loss, which are frequently overlooked in acute neurological settings.

Neuroimaging played a vital role in tracking the disease. Initial scans showed pontine involvement, which later progressed to the cerebellum as the disease advanced.

Initial T2-weighted MRI showing hyperintensities in the pons (arrowheads and arrows).
Follow-up MRI demonstrating progression of hyperintensities to the cerebellum (arrow).

Key Results

  • Treatment Refractoriness: The patient failed to improve after a standard five-day course of IVIG (0.4g/kg/day) for suspected BBE.
  • Systemic Manifestations: The emergence of autoimmune hemolytic anemia and Type 1 renal tubular acidosis provided strong evidence for a systemic autoimmune etiology.
  • Clinical Resolution: Following the diagnosis of pSS and initiation of cyclophosphamide and rituximab, the patient achieved complete resolution of hypersomnolence and ophthalmological symptoms at a two-month follow-up.

Conclusion and Limitations

This case underscores the complexity of post-COVID-19 neurological presentations. While viral infections can trigger specific para-infectious syndromes, they can also unmask systemic autoimmune diseases like pSS. Clinicians should maintain a high index of suspicion for "mimickers" when patients fail to respond to standard immunotherapies, ensuring that systemic clues like sicca symptoms are not neglected in the acute phase.

As a single case study (N=1), these findings cannot establish a definitive statistical link between SARS-CoV-2 and the onset of pSS. Future research should focus on the specific mechanisms by which viral infections trigger autoimmune flares.

Summary updated

Abstract

We present a case of acute external ophthalmoplegia, hypersomnolence, and ataxia occurring 5 days after an episode of SARS-CoV-2 upper respiratory tract infection. The patient’s serum returned positive for anti-GD1a antibodies. Guided by precedent cases, she was empirically started on a course of intravenous (IV) immunoglobulin for possible para-infectious Bickerstaff brainstem encephalitis (BBE). However, she failed to respond and subsequently developed autoimmune hemolytic anemia as well as renal tubular acidosis (type 1). Corroborative history from her family elucidated constitutional and sicca symptoms and she was eventually diagnosed with primary Sjögren syndrome (pSS) complicated by brainstem and cerebellar involvement. She was treated with IV cyclophosphamide and rituximab, after which her neurological deficits completely resolved at two months.
BibTeX
@inproceedings{lin2024case,
  author = {Shawn Zhi Zheng Lin and Hua Chan Ling and You‐Jiang Tan},
  title = {{A case of primary Sjögren syndrome masquerading as post-COVID Bickerstaff encephalitis}},
  booktitle = {Neurology},
  year = {2024},
  doi = {10.54029/2024dxc},
}
Figure